NEW YORK (GenomeWeb) – ArcherDx and GenomOncology today announced an agreement to co-market ArcherDx's next-generation sequencing assays alongside GenomOncology's data interpretation software.
Under the terms of the agreement, GenomOncology's GO Clinical Workbench will support interpretation of several ArcherDx assays, including the ALK, RET, ROS1, Solid Tumor, and Comprehensive Thyroid and Lung panels.
Financial and other terms of the deal were not disclosed.
"GenomOncology's GO Clinical Workbench will empower labs of all sizes to run and annotate ArcherDX NGS assays, from both RNA and DNA aberrations," Jill Stefanelli, ArcherDx director of pharma business development, said in a statement. "[I]nclusion of a rules-based reporting pipeline provides a much-needed step towards standardization of NGS methodologies."
GenomOncology CEO Manuel Glynias added that the goal of the collaboration would be to "facilitate the most streamlined and complete testing and decision support solutions for our clients."
ArcherDx's VariantPlex and FusionPlex assays detect oncogenic fusions, RNA levels, copy number variations, single nucleotide variants, and indels in formalin fixed paraffin-embedded (FFPE) samples. GenomOncology's GO Clinical Workbench is part of the GO Precision Medicine Portfolio, a suite of software tools designed to help healthcare institutions practice precision medicine. The partners did not say what steps would be needed to integrate the assays into the software workflow.
The deal is the latest in a string of partnerships ArcherDx has started this year, beginning with a deal with Qiagen in January, following Qiagen's purchase of ArcherDx's former parent company, Enzymatics. In September, the firm announced a deal to receive FFPE samples from BioChain, and in August it joined the Canadian National Access Project for Cancer Testing, a personalized medicine consortium.